The reduced net loss and cash raise improve near-term runway, but the company remains pre-revenue with significant R&D spend ahead. Traders should monitor regulatory feedback in Q1 2026 and progress toward Phase 2/3 initiation as key catalysts. Dilution risk may re-emerge if additional capital is needed beyond current runway.
Price Chart
Executive Summary
Silexion Therapeutics reported financial results for 2025, showing a reduced annual net loss of $11.9 million compared to $16.5 million in 2024, driven by lower G&A expenses. The company raised $18.6 million in gross proceeds, ended the year with $6.0 million in cash, and made key progress toward initiating a Phase 2/3 trial for SIL204 in pancreatic cancer in mid-2026. Despite advancing its pipeline, the company continues to burn cash, with R&D expenses increasing to $7.1 million for the year.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $11.9 million, down from $16.5 million in 2024.
- R&D expenses increased to $7.1 million in 2025 from $5.8 million in 2024.
- G&A expenses decreased to $4.5 million from $6.8 million year-over-year.
- Raised $18.6 million in gross proceeds in 2025 via public offerings and warrant exercises.
- Ended 2025 with $6.0 million in cash and cash equivalents.
- Completed toxicology studies and submitted Phase 2/3 clinical trial application in Israel; trial initiation expected in Q2 2026.
- Regulatory feedback anticipated by end of Q1 2026, with German filing planned by end of Q1 2026.
Financial Impact
Reduced net loss by $4.6 million YoY; R&D spend up 23%; cash balance increased by $4.8 million to $6.0M
Risk Factors
- High cash burn: R&D expenses increased significantly, and future trials will require substantial funding.
- Clinical trial delays: Initiation of Phase 2/3 trial is planned for mid-2026 but remains subject to regulatory approval.
- Dilution risk: Current cash may not be sufficient to complete late-stage trials without further financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257725 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1657 (−7.74%) |
Oct 5, 2026 22d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1657 (+36.95%) |
Sep 30, 2026 27d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1657 (−40.18%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1657 (+40.25%) |
Sep 29, 2026 28d ago | 8-K | $0.3180 $0.1650 | ▲ +48.11% | ▲ +48.77% | $0.1657 (+47.89%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 $0.1657 | ▲ +47.96% | ▲ +48.67% | $0.1657 (+47.96%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1657 (−33.29%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1657 (−33.29%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1657 (+33.29%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1657 (+60.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers